The U.S. Food & Drug Administration (FDA) Approves Updated LUPKYNIS® (voclosporin) Label to include Long-Term Data from the AURORA Clinical Program
UPDATE: New Aurinia Presentation Details at the 2024 Bloom Burton & Co. Healthcare Investor Conference
Aurinia Pharmaceuticals to Release First Quarter Financial and Operational Results on May 2, 2024
Aurinia Receives Exemptive Relief from Canadian Securities Regulators
Aurinia to Participate in Upcoming Investor Healthcare Conferences
Aurinia stock downgraded by Bloom Burton amid strategic challenges
Aurinia Discloses 2023 Year-End Financial and Operational Results
Aurinia Pharmaceuticals searched long and hard for a potential buyer, but, faced with a lack of serious offers, the biotech has resorted to trimming its workforce by a quarter and cleaning out its R&D pipeline.
Aurinia to Release 2023 Fourth Quarter and Full Year Financial Results
Aurinia Provides Preliminary Unaudited Fourth Quarter Net Revenue Results